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Background: The EGF receptor is an important 
therapeutic target.  
Results: Bispecific anti-EGFR-DARPins, 
alternative targeting molecules efficiently 
produced in bacteria, were shown to inhibit 
A431 cell proliferation and receptor recycling. 
Conclusion: One bispecific construct containing 
four DARPins showed a biological activity 
superior to that of the registered antibody 
cetuximab. 
Significance: Bispecific DARPins may form 
building blocks for tomorrow's cancer 
therapeutics. 
 
SUMMARY 
The epidermal growth factor receptor 
(EGFR) has been implicated in the 
development and progression of many 
tumors. While monoclonal antibodies directed 
against EGFR have been approved for the 
treatment of cancer in combination with 
chemotherapy, there are limitations in their 
clinical efficacy, necessitating the search for 
robust targeting molecules that can be 
equipped with new effector functions or show 
a new mechanism of action. Designed 
Ankyrin Repeat Proteins (DARPins) may 
provide the targeting component for such 
novel reagents. Previously, four DARPins 
were selected against EGFR with 
(sub)nanomolar affinity. As any targeting 
module should preferably be able to inhibit 
EGFR-mediated signaling, their effect on 
A431 cells overexpressing EGFR was 
examined: three of them were shown to 
inhibit proliferation by inducing G1-arrest, as 
seen for the FDA-approved antibody 
cetuximab. To understand this inhibitory 
mechanism, we mapped the epitopes of the 
DARPins using yeast surface display. The 
epitopes for the biologically active DARPins 
overlapped with the epidermal growth factor 
(EGF) binding site, whereas the fourth 
DARPin bound to a different domain, 
explaining the lack of a biological effect. To 
optimize the biological activity of the 
DARPins, we combined two DARPins binding 
to different epitopes with a flexible linker or 
with a leucine zipper, leading to a 
homodimer. The latter DARPin was able to 
reduce surface EGFR by inhibiting receptor 
recycling, leading to a dramatic decrease in 
cell viability. These results indicate that 
multispecific EGFR-specific DARPins are 
superior to cetuximab and may form the basis 
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of new opportunities in tumor targeting and 
tumor therapy.     
  The epidermal growth factor receptor 
(EGFR/ErbB1/HER1) was the first receptor 
identified of the ErbB family of receptor tyrosine 
kinases (1). These receptors, anchored in the 
cytoplasmic membrane, share a similar structure 
that is composed of an extracellular region 
containing a ligand-binding site, a 
transmembrane region, and a cytoplasmic 
tyrosine kinase domain (2, 3). The extracellular 
region itself is divided into four domains (I-IV). 
Domain I and III make direct contacts to the 
ligand, whereas domain II plays a role in 
receptor dimerization upon ligand binding (4). 
EGFR is known to bind a variety of ligands, 
including epidermal growth factor (EGF) and 
transforming growth factor-α (TGF-α) (5). 
These ligands can activate the receptor through 
inducing receptor dimerization, leading to 
transphosphorylation of key tyrosine residues. 
These residues provide specific docking sites for 
cytoplasmic proteins, whose binding initiates the 
signal for the activation of several downstream 
signaling pathways (6-8). Consequently, EGFR 
plays a pivotal role in cell proliferation and 
differentiation, and survival of normal epithelial 
tissue (9, 10). Signal attenuation is achieved by 
phosphatase activity. In addition, a ligand-
induced alteration of EGFR trafficking leads to 
accelerated internalization of the receptor and a 
decrease in receptor recycling (11).  
 EGFR is constitutively expressed on many 
normal tissues, including the skin and hair 
follicles. The rationale for choosing EGFR as a 
target in cancer therapy was based on the 
observation that EGFR is overexpressed on the 
surface of many human cancers, including 
colorectal cancer, non-small cell cancer of the 
lung and gliomas (12). This overexpression is 
correlated with increased resistance to 
chemotherapy, more aggressive disease, and 
poor prognosis (6, 13). Moreover, increased 
receptor expression is often correlated with 
increased ligand production by the same tumor 
cells (1), leading to receptor activation by an 
autocrine stimulatory pathway. In some 
glioblastomas a mutant EGFR is expressed 
which contains a deletion in the extracellular 
domain, leading to a constitutively active 
receptor (14). 
 A number of monoclonal antibodies 
(mAbs) directed against EGFR have been 
extensively investigated for their abilities to slow 
or even inhibit tumor growth (15). FDA-
approved antibodies cetuximab and 
panitumumab both bind to an epitope that 
partially overlaps the ligand-binding site of 
EGFR on domain III. Thus, the receptor is 
sterically prevented from adopting the open 
conformation required for dimerization. 
Consequently, autophosphorylation and receptor 
activation is inhibited (10, 16, 17). Nonetheless, 
the National Institute for Health and Clinical 
Excellence (NICE) for the U.K. 
(www.nice.org.uk) no longer recommends 
cetuximab in the treatment of metastatic 
colorectal cancer, based on an evaluation of an 
unfavorable ratio of clinical and cost 
effectiveness. The rather modest clinical benefits 
seen with cetuximab, an IgG, make molecular 
formats with novel effector functions, as well as 
novel multispecific formats with a new 
mechanism of action very desirable. In order to 
have an impact, such molecules must be easy to 
engineer and produce, and should be very robust 
to a wide range of modifications.  
 Several alternative binding scaffolds have 
been developed in recent years (18, 19), of 
which Designed Ankyrin Repeat Proteins 
(DARPins) are a particularly promising example 
(20). Derived from naturally occurring ankyrin 
repeat proteins, they have been engineered by a 
consensus design approach. DARPins have been 
selected from libraries via ribosome display or 
phage display to bind to a wide range of 
different protein targets (18, 21-26). DARPins 
are very well expressed in the cytoplasm of 
Escherichia coli, monomeric in solution, highly 
soluble and very stable; moreover, they can 
easily be fused to other protein domains to 
generate multispecific or multivalent DARPins, 
or be chemically conjugated to other molecules 
(27-29). Thus, the therapeutic application of 
DARPins can be extended over what would be 
possible with traditional antibodies. 
 Previously, four DARPins were selected 
by phage display against the soluble recombinant 
ectodomain of EGFR (21). These DARPins all 
showed monomeric behavior in size exclusion 
chromatography; additionally, their affinities 
were determined to be (sub)nanomolar (Table I). 
Using the A431 cell line, which has been 
developed as a widely used model system for 
testing anti-EGFR activity (30), we investigated 
the biological activity of these DARPins and 
compared them to that of cetuximab. Three 
DARPins were found to show biological activity 
on A431 cells, though their effect was not better 
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than the effect of cetuximab. The fourth DARPin 
did not show any biological activity.
 Recently, it was established that 
combinations of noncompetitive mAbs can 
synergistically reduce surface EGFR levels, 
resulting in enhanced tumor cell killing (31, 32). 
To apply this principle to the selected DARPins, 
we first mapped the epitope of the four binders. 
We combined the non-competitive DARPins 
E01 and E69 in bispecific formats, using a 
flexible linker and a leucine zipper, respectively. 
Bivalent constructs with a flexible linker will be 
denoted as DARPin_GS_DARPin (to denote the 
(G4S)2 linker), whereas the leucine zipper 
constructs, which are both bispecific and 
bivalent and thus contain four DARPins, will be 
indicated by DARPin_LZx_DARPin. In 
particular, the E69_LZ3_E01 construct showed a 
dramatically improved biological activity 
compared to cetuximab. It could even reduce 
surface EGFR levels of A431 cells by inhibiting 
receptor recycling. These results indicate that 
bispecific DARPins hold great promise in tumor 
targeting strategies. 
 
EXPERIMENTAL PROCEDURES 
 Cells and culture conditions – A431 
cells were obtained from ATCC (ATCC number 
CRL-2592). Cells were maintained in DMEM 
culture media (Sigma, Steinheim, Germany) 
supplemented with 10% v/v heat-inactivated 
fetal calf serum (FCS, PAA GmbH, Pasching, 
Austria) and 1% v/v penicillin-G/streptomycin 
(Sigma) in a humidified incubator with 5% CO2. 
 Reagents – Cetuximab was purchased 
from Merck (Darmstadt, Germany). 
Recombinant human epidermal growth factor 
(EGF) was purchased from Jena Bioscience 
GmbH (Jena, Germany). All chemicals used for 
overexpression and purification of the DARPins 
were purchased from Sigma-Aldrich, unless 
stated otherwise.   
 Cloning, expression and purification of 
DARPins – The ORFs for DARPins E01, E67, 
E68 and E69 recognizing EGFR and control 
DARPin Off7 were digested with BamHI and 
HindIII (Fermentas, Vilnius, Lithuania) and 
ligated into the expression vectors pQE30 and 
pQE30_sfGFP, the latter to create DARPins     
C-terminally fused to superfolder GFP (33). 
After transformation of E. coli XL-1 blue, the 
proteins were overexpressed, purified via their 
N-terminal MRGSH6-tag with Ni-NTA 
superflow resin (Qiagen, Hilden, Germany), and 
subsequently dialyzed against PBS pH 7.2 (34). 
 Bispecific constructs of DARPins of E01 
and E69 were made as described in (28). Briefly, 
the C-terminal DARPin was digested with BsaI 
and BglII, and subsequently ligated into pQIBI 
vectors. The bispecific construct either had a 
flexible (G4S)2-linker between the two DARPins, 
or a leucine zipper; in the latter construct, the 
leucine zipper was both N-terminally and C-
terminally flanked by different linkers (cf. Fig. 
5A). The N-terminal DARPin was digested with 
BamHI and HindIII and ligated into the 
respective pQIBI vector. After transformation of 
E. coli XL-1 blue, the proteins were 
overexpressed, purified via their N-terminal 
MRGSH6-tag, and subsequently dialyzed against 
PBS pH 7.2 (34). 
 DARPins E01 and E69_LZ3_E01 were 
coupled to Alexa Fluor 488 using maleimide 
chemistry. For this purpose, E01 was first 
subcloned into the vector pQE30_Cys after 
digestion with BamHI and HindIII. This vector 
has the sequence GSC appended to the             
C-terminus of the DARPin. In the 
E69_LZ3_E01 variant, the Cys residue present 
in the second repeat of E69 was first removed 
with the Quikchange kit (Stratagene, La Jolla, 
CA). Next, the C-terminal DARPin E01 was 
exchanged for E01_GSC after digestion with 
AgeI and NheI and subsequent ligation. After 
transformation of E. coli XL-1 blue, the proteins 
were overexpressed and purified using the N-
terminal MRGSH6-tag. The proteins were 
dialyzed against HBS pH 7.5. 
  Binding of DARPin_sfGFP fusions to cells 
– A431 cells were trypsinized and resuspended 
in ice-cold FACS buffer (PBS pH 7.4, 1% BSA 
(Fluka), 0.1% sodium azide). For 1 hour, 1·106 
cells were incubated with 100 nM of monovalent 
DARPin-sfGFP fusions on ice. As a positive 
control, cells were incubated with 100 nM 
cetuximab, which was subsequently labeled with 
an anti-human-Fab FITC-conjugated antibody 
(Jackson ImmunoResearch, Suffolk, UK). 
Off7_sfGFP and sfGFP itself were used as 
negative controls. The binding of the DARPins 
and cetuximab was examined using flow 
cytometry using a BD Biosciences 
FACSCantoII. Fluorescence data were analyzed 
using FlowJo software.                                       
  To determine the different epitopes of the 
DARPins, competition experiments were 
performed. One million cells were incubated 
with 50 nM of one DARPin-GFP fusion, with a 
series of concentrations of a second unlabeled 
DARPin or cetuximab as competitor. After a    
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1-hour incubation on ice, cells were washed 
twice with FACS buffer and the fluorescence 
was measured by flow cytometry.            
  Cell viability assays – For growth 
inhibition assays, A431 cells were seeded at a 
density of 3000 cells/well in DMEM 
supplemented with 1% v/v FCS. After 24 h, cells 
were treated with cetuximab or DARPins at 
different concentrations. Cells were incubated 
for another 72 h, after which cells were washed 
and incubated with 2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT) (Roche) for 4 h at 37°C. Absorbance was 
measured at 540 nm in 96-well plates and 
expressed as a percentage of the untreated 
controls. 
  For clonogenic assays, A431 cells were 
seeded at a density of 300 cells/well in DMEM 
supplemented with 10% v/v FCS. After 2 h, 100 
nM DARPin or cetuximab was added to the 
respective well. The treatment was terminated 
after 7 days: cells were washed twice with PBS 
and allowed to proliferate in DMEM 
supplemented with 10% v/v FCS for another 
7 days. Cells were then stained with 0.1% crystal 
violet in PBS for at least 30 min at room 
temperature, after which colonies were counted. 
Clonogenic survival was expressed as the 
percentage of colony-forming units in treated 
cultures relative to untreated cultures (35, 36). 
 The concentration dependence of 
E69_LZ3_E01 was determined by the 
clonogenic assay as described above. Here, cells 
were treated with different concentrations, 
ranging from 10 pM to 1 µM. Cetuximab and 
Off7 were used as positive and negative controls, 
respectively. 
  Cell cycle analysis – A431 cells were 
seeded and plated onto 6-well plates at a density 
of 1·106 cells/well. Cells were maintained in 
DMEM, supplemented with 1% v/v FCS. After 
24 h, cells were incubated alone or in the 
presence of 100 nM cetuximab or DARPin for 
another 24 h (37). Cells were permeabilized 
using 70% ethanol and cell cycle distribution 
was assessed by flow cytometry using propidium 
iodide staining (38). Single cells were gated and 
the resulting DNA distributions were analyzed 
using the FlowJo software. 
 Epitope mapping of DARPins – The 
epitopes of DARPins E01 and E69 were mapped 
according to the methods described in (39-41). 
Briefly, domain-level epitope mapping of E69 
was performed by testing binding to yeast 
surface-displayed EGFR fragments. 106 yeast 
cells were incubated with 150 nM E69 for 
30 min at 25°C, and subsequently labeled with 
biotinylated anti-penta-His antibody (1:100) 
(Qiagen) and streptavidin-PE (1:50) (Invitrogen) 
at 4oC. Fluorescence data were obtained using a 
Coulter Epics XL flow cytometer (Beckman-
Coulter). Binding of E01 to yeast surface-
displayed 404SG (see below) was performed in 
the same way.    
 Further fine epitope mapping (40) was 
performed using an error-prone PCR library of 
single point mutations of 404SG. 404SG is an 
EGFR ectodomain mutant carrying the point 
mutations A62T, L69H, F380S, and S418G, 
which allow the ectodomain to be correctly 
displayed on the surface of yeast (42). Misfolded 
404SG EGFR variants were first removed 
through one round of FACS sorting for retention 
of binding to either 50 nM mAb 528 (binding to 
domain III) or mAb EGFR1 (binding to domain 
II) (Abcam, Cambridge MA, USA) (39, 40). 
Sorting was performed using either a 
DakoCytomation (Carpinteria, CA, USA), 
MoFlo or Aria (BD Biosciences) FACS machine 
at the MIT flow cytometry core facility. 
mAb 528 was shown not to compete with E01 
for binding to EGFR (data not shown). 
Therefore, the mAb 528-positive library was 
sorted for loss of binding to E01 (sort 1 at 50 
nM, sorts 2 and 3 at 100 nM DARPin). EGFR1 
mAb had previously been shown not to compete 
with E69 for binding to EGFR (data not shown). 
Thus, the mAb EGFR1-positive library was 
sorted for loss of binding to E69 (sort 1 at 150 
nM, sorts 2 and 3 at 300 nM E69). Plasmids 
from the enriched populations were recovered 
using a Zymoprep kit (Zymo Research, Irvine, 
CA, USA) and sequenced. Yeast was 
transformed with the individual sequenced 
mutants and re-tested to confirm proper folding 
of the EGFR mutants (by binding to the 
antibodies) and loss of binding to the DARPins. 
All EGFR protein images were generated 
using PyMOL software (DeLano Scientific LLC, 
at http://www.pymol.org) from PDB structure 
1IVO (chain A) (4). 
 Western blotting analysis – A431 cells 
were seeded and plated onto 6-well plates at a 
density of 1·106 cells/well. Cells were 
maintained in DMEM supplemented with 
10% v/v FCS. After 24 h, the medium was 
changed to 1% v/v FCS for serum starvation in 
the presence of 100 nM cetuximab or DARPin 
for another 24 h. As a control, cells were 
incubated with serum starvation medium alone. 
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After this treatment, cells were stimulated with 
10 ng/ml (1.6 nM) EGF for 15 min at 37°C and 
subsequently washed with PBS and incubated in 
lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 
0.5% w/v sodium deoxycholate, 0.1% v/v      
NP-40, 0.1% v/v SDS, 1 mM sodium 
orthovanadate, 1 tablet PhosStop (Roche)) (43-
45). Total protein concentration in the lysates 
was determined by a BCA assay (Sigma) and 
20 µg of total protein per sample was separated 
by 10% SDS-PAGE and transferred to an 
ImmobilonFL membrane (Merck Millipore, 
Billerica, MA, USA) by Western wet blotting. 
After blocking of the membranes with Odyssey 
blocking buffer (Li-Cor, Bad Homburg, 
Germany), the membranes were probed with the 
following antibodies from Cell Signaling 
Technologies (Beverly, MA, USA): α-phospho-
EGFR (Tyr1068), α-EGFR, α-phospho-Akt 
(Ser473), α-Akt, α-phospho-ERK1/2 (phospho-
p44/p42, Thr202/Tyr204), and α-ERK1/2. The 
anti-β-actin antibody was purchased from 
Sigma. After incubation with secondary IR-Dye-
conjugated antibodies (Li-Cor), immunoblots 
were detected and quantified using the Odyssey 
software (Li-Cor).  
 Fluorophore labeling of DARPins – 
DARPins E01 and E69_LZ3_E01 were labeled 
with Alexa Fluor 488 C5-maleimide (Molecular 
Probes, Invitrogen, Lucerne, Switzerland). 
DARPins were reduced under argon with 50 mM 
TCEP for 30 minutes. Then, TCEP was removed 
in a desalting step. DARPins were labeled with 
Alexa Fluor 488 at a protein:dye ratio of 3:1. 
The labeling reaction was allowed to proceed for 
1 hour at room temperature. Unlabeled DARPins 
were separated from their labeled counterparts 
via anion exchange chromatography on a monoQ 
column using an NaCl gradient (50 mM Tris 
pH 8.5). 
 Internalization and recycling assays – The 
inhibition of receptor recycling was examined 
using the method described in (32). Briefly, 
A431 cells were serum starved for 16 h, after 
which they were harvested in serum-free 
medium. For 2 h, 2·105 cells were incubated 
with E01_Alexa Fluor 488 alone or in 
combination with E69, or with 
E69_LZ3_E01_Alexa Fluor 488 at 37°C to 
allow for internalization. Cells were then treated 
with 50 µg/ml anti-Alexa-488 quenching 
antibody (Invitrogen) for 30 minutes on ice and 
subsequently chased with unlabeled DARPin at 
37°C for the indicated length of time in the 
presence of the quenching antibody. Cells were 
then returned to ice and washed twice with PBS. 
The subsequently measured fluorescence signal 
originated from the internalized labeled 
DARPins. The fluorescence signal was 
examined by flow cytometry using a BD 
Biosciences FACSCantoII. Fluorescence data 
were analyzed using FlowJo software; the 
percent unchased signal was calculated relative 
to cells that were not returned to 37°C after 
quenching.     To 
verify the ability of E69_LZ3_E01 to inhibit 
receptor recycling, a monensin recycling assay 
was performed. A431 cells were serum starved 
for 16 h and subsequently harvested in serum-
free medium to a concentration of 1·106 cells/ml. 
Cells were either treated with 50 µM monensin 
for 20 minutes at 37°C, or 100 nM 
E69_LZ3_E01. Incubation was continued at 
37°C for the indicated time. Cells were then 
washed, acid stripped (0.2 M acetic acid, 0.5 M 
NaCl, pH 2.5), and washed again with PBS. 
Then, cells were incubated on ice with 100 nM 
E69_LZ3_E01_Alexa Fluor 488. After 45 
minutes, cells were washed. The binding of the 
DARPin was analyzed by flow cytometry using 
a FACSCantoII. Fluorescence data were 
analyzed using FlowJo software. 
 
RESULTS 
 Selected DARPins bind to EGFR on A431 
cells – Since the DARPins were selected against 
recombinant purified EGFR ectodomain, we first 
assessed their binding to the native target 
expressed on A431 cells. This cell line shows a 
high overexpression of EGFR (~3·106 
receptors/cell) (46). A431 cells were incubated 
with DARPin_sfGFP fusion proteins, and the 
subsequent change in fluorescence signal was 
measured using flow cytometry. It was shown 
that all DARPins and cetuximab elicited a shift 
in the fluorescence signal significantly greater 
than that of the negative control DARPin 
Off7_sfGFP and of sfGFP alone (Suppl. 
Fig. S1).  
DARPin_sfGFP fusion proteins were 
competed with EGF, cetuximab and unfused 
DARPins without GFP to verify specific binding 
and determine possible overlapping binding 
epitopes. DARPins E01, E67 and E68 could be 
competed with EGF as well as with cetuximab 
and with one another, whereas DARPin E69 
could only be competed with E69 itself 
(Fig. 1A). Thus, the binding epitope of E01, E67 
and E68 must at least partly overlap with that of 
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cetuximab and EGF, while E69 binds to an 
epitope located elsewhere.   
 A431 cell proliferation is inhibited by 
monovalent DARPins – The influence of 
DARPins on A431 cell viability was tested by 
using XTT assays as well as clonogenic assays. 
Cetuximab decreased cell growth by 30% in 
XTT assays at 100 nM. DARPins E01, E67 and 
E68 decreased cell viability to almost the same 
level as cetuximab, albeit at higher DARPin 
concentrations. In contrast, E69 did not show 
any influence on cell viability, nor did the 
negative control DARPin Off7 (Fig. 1B). 
 In the clonogenic assays, DARPins E01, 
E67 and E68 slightly inhibited the formation of 
colonies compared to cetuximab, whereas E69 
and Off7 did not affect colony formation 
(Fig. 1C). Thus, the growth-inhibitory effect on 
A431 viability was restricted to DARPins E01, 
E67 and E68, which all share an overlapping 
epitope with cetuximab. 
 After 24 h incubation, the effect of 
DARPins on the cell cycle was assessed by 
staining the cells’ DNA with propidium iodide 
followed by flow cytometric analysis. DARPins 
E01, E68, and, to a lesser extent, E67 were 
found to induce G1-arrest, comparable to the 
effect of cetuximab (Fig. 1D). The effect of these 
DARPins on the cell cycle was specific, as both 
the negative control DARPin Off7 and DARPin 
E69 did not appear to have an effect. 
 Epitope mapping of DARPins – From the 
competition experiments in flow cytometry 
(Table I), it could be inferred that DARPins E01, 
E67, and E68 bind to domain III of EGFR: they 
competed with both cetuximab and EGF for 
binding (9). However, the competition data did 
not lead to any information on the E69 epitope, 
since it could not be competed with any of the 
other DARPins or with cetuximab. Therefore, 
domain-level epitope mapping was first 
performed on E69 by using EGFR fragments 
displayed on the surface of yeast (39). 
Previously, it had been found that the full wild-
type ectodomain of EGFR is not correctly 
displayed on the surface of yeast, but the mutant 
404SG is (42). 404SG contains two point 
mutations in domain I (A62T and L69H) as well 
as two point mutations in domain III (F380S and 
S418G). The 404SG EGFR ectodomain mutant 
was used for both domain-level and subsequent 
fine epitope mapping. E01, E67, and E68 bound 
to yeast-displayed 404SG, with E67 giving a 
lower binding signal, possibly due to the 
mutations in 404SG (data not shown). 
 E69 showed binding to 404SG and EGFR 
1-294, and very slight binding to EGFR 1-176 
(Suppl. Table SI). However, no binding to EGFR 
1-124 was detected. Therefore, it appeared that 
E69 bound to either domain I or domain II. 
However, since it cannot be excluded that 
fragments not showing E69 binding could be 
misfolded, from these experiments the location 
of the epitope can therefore only be specified to 
lie between residues 1 and 294. Additional 
competition experiments were performed with 
mAbs 199.12 and ICR10, which bind to domain 
I (39). DARPin E69 competed with these 
antibodies for binding to 404SG on the surface 
of yeast (data not shown), suggesting a domain I 
epitope for E69. Indeed, the fine mapping of the 
epitope confirmed this assignment (see below). 
 DARPins E01, E68 and E69 were selected 
for further fine epitope mapping, since they bind 
to different epitopes. The results are summarized 
in Fig. 2, showing the binding epitopes mapped 
onto the EGF-bound active conformation of the 
receptor. For defining the epitopes at residue 
level resolution, a library of single point mutants 
of 404SG was created; this library was sorted for 
loss of binding to the DARPin being mapped in 
order to determine the residues important for 
DARPin binding.  
 Besides sorting for a loss of binding, the 
library must also be sorted for retention of 
conformation, i.e. to ensure that all mutants 
being assessed are correctly folded. For this 
purpose, the EGFR library was sorted for 
positive binding to the conformation-specific 
mAb 528 (an anti-domain III antibody) and, 
subsequently, for loss of binding to E01 and 
E68. From each enriched population 48 clones 
were sequenced, yielding 14 residues for both 
epitopes. As shown in Suppl. Table SII many 
residues were shared between E01 and E68. 
Mutants Q408H, H409Y, Q411K, K465I, and 
G471D showed a loss of E01 binding and were 
tested against E68. These variants retained their 
E68 binding. Conversely, mutant Q348H 
showed a loss of E68 binding, but retained its 
E01 binding. Other mutants, analyzed for their 
loss of binding to one DARPin (F412V, A415E, 
I438K, K463E/I/N/T, K465E, I467M/T, N469D) 
were not assayed for loss of binding to the other 
DARPin. G418 was identified as an epitope 
residue for both E01 and E68, but the 
interpretation of these data may be ambiguous 
since this residue was originally mutated from 
serine to glycine in the 404SG variant. The 
epitopes of E01 and E68 are shown in Fig. 2A. 
 at SM
AC Consortium
 - University of Zürich, on January 7, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Bispecific EGFR-DARPins inhibit A431 cell proliferation 
 7 
As expected, both DARPins bind to domain III. 
Many epitope residues are shared with 
cetuximab, which is consistent with the 
competition data (Table I). In addition, a 
DARPin bound to epitopes of E01 and E68 
would appear to sterically clash with the EGF 
ligand, suggesting a mechanism for the ability of 
these DARPins to inhibit the growth of A431 
cells. 
 For the mapping of E69, the EGFR mutant 
library was first sorted for binding to mAb 
EGFR1 to remove misfolded EGFR mutants. 
Then, after three sorts for loss of binding to E69, 
enriched populations were sequenced; from 98 
clones, the epitope of E69 could be localized to 
10 residues in domain I (Table III). The E69 
epitope is shown in Fig. 2B. Fig. 2C illustrates 
the relative orientation of E01 and E69.  
 Bispecific DARPins affect A431 cell 
viability and proliferation similar to cetuximab – 
As several studies previously reported 
cooperative effects of mAb combinations (31, 
32, 47, 48), we constructed bispecific 
multivalent molecules to further optimize the 
therapeutic potential of the DARPins by 
increasing the avidity. Since the epitopes of the 
four DARPins were mapped, two DARPins 
targeting different epitopes were chosen. E01, 
having the highest affinity, and E69 were 
combined in a bivalent construct with a flexible 
(Gly4Ser)2 linker (termed E01_GS_E69 and 
E69_GS_E01, Fig. 3A). A more rigid construct 
that was at the same time bispecific and bivalent 
for each epitope was created by making use of a 
leucine zipper (termed E69_LZx_E01 and 
E01_LZx_E69, Fig. 3B). For this format, 
different linker lengths were tested between the 
DARPins and the leucine zipper (Fig. 5A); the 
shortest linker, consisting of G3S (variant LZ3), 
proved to be the best (Fig. 5). 
 The bispecific constructs without leucine 
zipper were able to affect cell viability and 
induce G1 arrest to the same extent as the 1:1 
molecular mixture of the monovalent DARPins 
E01 and E69, and cetuximab (Fig. 4A and C). 
This suggests that the observed effect is mainly 
due to E01 binding, as E69 itself has no effect. 
The slightly better performance of E01_GS_E69 
and E69_GS_E01 than the E01/E69 mixture at 
intermediate concentrations is probably a simple 
avidity effect. In contrast, in the clonogenic 
assay, E01_GS_E69 and E69_GS_E01 were not 
able to inhibit colony formation to a significant 
extent (Fig. 4B). Considering the experimental 
error, no significant difference in the inhibition 
of A431 proliferation was seen between the two 
orientations in any of the assays. 
 In contrast, for the leucine zipper 
constructs, a difference in the biological activity 
was clearly observed between both orientations 
(Fig. 5B, C and D). The E69_LZ3_E01 molecule 
was capable of inhibiting cell viability already at 
low concentrations, whereas the opposite 
orientation E01_LZ3_E69 was not. Differences 
in the extent of cell cycle arrest were seen as 
well (Fig. 5F and G). It was shown by FACS 
competition measurements that E69_LZ3_E01 
blocks epitopes of labeled E69 or labeled E01 
efficiently, while E01_LZ3_E69 does not 
(Suppl. Fig. S2). Since the cells were exposed to 
the multivalent DARPins at 4°C for 30 min, it is 
unlikely that significant internalization was 
triggered. The DARPins were incubated in a 1:1 
molar ratio with EGFR expressed on A431 cells, 
and it might well be that not all epitopes were 
covered in this experiment. Nonetheless, it is 
clear that E69_LZ3_E01 more efficiently blocks 
binding of either labeled monovalent DARPin, 
suggesting that its binding sites are arranged for 
a better fit to the EGFR structure than 
E01_LZ3_E69. 
 In addition, E69_LZ3_E01 was more 
effective in inhibiting A431 proliferation in the 
clonogenic assay than cetuximab with an IC50 of 
approximately 100 nM (Fig. 5D and E). It is 
interesting to note that the decrease in 
proliferation is very gradual with concentration. 
This is consistent with the idea that only a small 
number of receptors need to be phosphorylated 
in order to initiate significant downstream 
signaling (49). To further investigate these 
effects, A431 cells were treated with the 
DARPins and the effect on cell signaling was 
examined by Western blot. In addition to E01, 
all bispecific DARPins were able to inhibit 
phosphorylation of EGFR (Y1068) (Fig. 6A). 
All bispecific DARPins were more effective in 
the inhibition of the phosphorylation of ERK 
(p44/p42) than cetuximab (Fig. 6B). In the case 
of Akt, both cetuximab and E69_LZ3_E01 were 
effective in inhibiting phosphorylation (Fig. 6C); 
in contrast, the other DARPins were not as 
effective.  
 Interestingly, when examining total EGFR 
levels, it was found that E69_LZ3_E01 
dramatically reduced total EGFR (Fig. 6A); the 
other constructs and cetuximab did not show this 
effect.    
 E69_LZ3_E01 effectively inhibits receptor 
recycling – Since the amount of total EGFR was 
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reduced in Western blot after treating A431 cells 
with E69_LZ3_E01, EGFR receptor recycling 
was investigated according to (32). 
E69_LZ3_E01 and monovalent E01 were 
coupled to Alexa Fluor 488 C5-maleimide. The 
fluorescence originating from internalized 
DARPins was measured after quenching the 
fluorescence signal from DARPins that were not 
internalized with an anti-Alexa antibody. In 
addition, fluorescence from DARPins that would 
recycle back to the cell surface together with 
EGFR was competed with an excess of 
unlabeled DARPin. Monovalent E01 both alone 
and in combination with monovalent E69 was 
not able to inhibit receptor recycling. In contrast, 
E69_LZ3_E01 effectively inhibited receptor 
recycling (Fig. 7A and C).   
  This finding was supported by a second 
assay, in which monensin was used as a positive 
control to inhibit protein transport and EGFR 
recycling (50). The surface EGFR level was 
assessed after treatment with E69_LZ3_E01 and 
the positive control monensin. As expected, the 
surface EGFR level was decreased after 
treatment with either monensin or 
E69_LZ3_E01 (Fig. 7B). Thus, E69_LZ3_E01 
clearly inhibits receptor recycling, which 
corroborates with the down-regulation of EGFR 
seen in Western blot. 
 
DISCUSSION 
 The EGF receptor is a valuable target for 
tumor therapy (15). While the clinical benefits of 
monoclonal anti-EGFR antibodies in the IgG 
format have so far been rather modest, it is likely 
that different targeting molecules with novel 
effector functions can ultimately lead to 
improved tumor therapies. Ideally, any such 
targeting molecule should be able, in addition to 
the effect of any potential payload, to inhibit 
signaling via EGFR. Since DARPins are 
particularly robust and thus suitable for such 
tumor targeting constructs (27), we investigated 
the inhibitory properties of previously selected 
anti-EGFR DARPins (21) on the well-
characterized A431 cell line (30). The results 
were correlated with a determination of their 
conformational epitopes at amino acid-level 
resolution. We then combined two non-
competitive DARPins in different bispecific 
formats to further optimize the biological 
activity. 
 DARPins with (sub)nanomolar affinities 
had been selected against the purified 
extracellular region of EGFR (sEGFR) (21) 
(Table I). To address the question whether the 
selected DARPins would have biological effects 
similar to cetuximab, we carried out a number of 
cell-based assays. The anti-EGFR DARPins fall 
into two groups. DARPins E01, E67 and E68 
decrease cell viability and inhibit cell growth, as 
seen in XTT and clonogenic assays, and induce 
G1-arrest; DARPin E69 has no such effect (Fig. 
1). In addition, the negative control DARPin 
Off7 shows no biological activity, indicating that 
the observed effects of DARPins E01, E67 and 
E68 on A431 cells are EGFR-specific.  
Our flow cytometry competition 
experiments showed that DARPins E01, E67 and 
E68 competed with cetuximab as well as EGF 
for binding, whereas E69 did not (Table I). 
These findings are consistent with the results 
from epitope mapping by yeast surface display 
of EGFR (39, 40) (Fig. 2). An error-prone 
library of sEGFR ectodomain variants was 
displayed on the surface of yeast and was 
selected for loss of binding to the DARPins. This 
method has the advantage that non-linear 
epitopes can be precisely mapped at residue 
resolution. Since the library was first sorted for 
binding to conformation-specific control 
antibodies binding to the same domain, loss of 
binding is not simply due to a loss of structure in 
the identified EGFR mutants. 
 Using this method, we determined that the 
epitopes of DARPins E01 and E68 are located 
exclusively on domain III (Suppl. Table SIII). 
Similar to cetuximab, E01 and E68 bind epitopes 
located near the C-terminal end of domain III. 
Binding of DARPins E01 and E68 interferes 
with hydrophobic interactions of the receptor 
with the ligand. Both DARPins bind to residue 
A415, which is located in a hydrophobic pocket; 
compared to cetuximab, which does not bind to 
this residue, the DARPins are packed more 
deeply into the binding pocket in this region of 
EGFR. In addition, the hydrogen bond of Q384 
of EGFR with the main chain carbonyl and 
amide groups of Q43 and R45 of EGF and the 
stabilization of the C-terminal carboxyl group of 
EGF by K465 of EGFR are disrupted by 
DARPin binding. Thus, E01 and E68 exhibit 
their activity via physically blocking the 
receptor-ligand interaction. 
 The E69 epitope was localized to ten 
residues in EGFR domain I (Suppl. Tables SI 
and SII). EGF does interact with domain I, 
although these residues are located towards the 
N-terminal end of domain I (4); the epitope for 
E69 is in fact located near the         C-terminal 
 at SM
AC Consortium
 - University of Zürich, on January 7, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Bispecific EGFR-DARPins inhibit A431 cell proliferation 
 9 
end of domain I. Based on the epitope residues 
determined by the yeast display method, it does 
not appear that EGF binding would be physically 
blocked by this DARPin. Consistent with our 
data on the E69 epitope, we determined that cell 
proliferation and survival are not affected by 
treatment with DARPin E69.  
Cetuximab has a mechanism of action 
similar to E01 and E68. This mAb was co-
crystallized with the receptor; the 3D structure 
revealed that cetuximab exerts its growth 
inhibitory activity by partly occluding an epitope 
overlapping with the EGF-binding site on 
domain III of EGFR, while the VH region of the 
antibody sterically blocks domain I (9). In this 
way, the receptor is prevented from adopting the 
open conformation required for receptor 
dimerization and activation. In the past, a 
number of other anti-EGFR mAbs has been 
developed by immunizing mice with human 
EGFR-overexpressing tumor cells (51–54). The 
antibody IMC-11F8, which has been selected 
from a Fab library by competing against 
cetuximab and screening for inhibition of EGFR 
signaling inhibition, was found to bind to the 
same epitope as cetuximab in the same 
orientation (55). Matuzumab, the humanized 
form of the murine antibody mAb425, binds to a 
different epitope on domain III of EGFR and 
does not block EGF binding, but prevents the 
conformational change of the receptor required 
for dimerization (56). mAb806 and mAb175, 
which have been raised against a deletion variant 
of EGFR, recognize an epitope in domain II, 
which is buried in the wild-type receptor in the 
tethered, non-activated conformation (57). 
Apparently, this epitope is recognized on wild-
type receptors on tumor cells, but not on normal 
cells. Other antibodies against EGFR are in 
development, whose epitopes have not yet been 
crystallographically defined (58). 
 The activity of DARPins E01, E67, and 
E68 at high concentrations is comparable to that 
of cetuximab. However, despite their high 
affinity for the target (21) higher concentrations 
are needed to affect the short-term cell viability 
in XTT assays. Cetuximab has an avidity of 
1 nM on A431 cells (47)), but its bivalent nature 
has been shown to induce receptor 
internalization (47, 59), and antibody-induced 
EGFR dimerization was necessary for down-
regulation of EGFR. This antibody-induced 
dimerization does not lead to receptor activation. 
The monovalent Fab' derived from cetuximab 
(47, 60) had a less pronounced effect on cell 
proliferation and did not induce receptor down-
regulation (47). However, the monovalent Fab’ 
was still able to inhibit receptor phosphorylation, 
indicating that inhibition of the signaling 
pathways is not dependent on receptor down-
regulation which would require bivalency (61). 
E01 similarly inhibits receptor phosphorylation 
(Fig. 5), but hardly affects ERK/Akt downstream 
signaling. It has been shown previously that 
signaling through EGFR can still occur despite 
the absence of EGFR phosphorylation (62–64). 
ERK and Akt can still be phosphorylated, though 
other receptors and pathways might be involved. 
In addition, only a small number of receptors 
need to be phosphorylated in order to initiate 
significant downstream signaling (49). Possibly, 
bivalent binding to the receptor is a prerequisite 
to abolish this effect. 
 Thus, to optimize the effect of the 
DARPins, we constructed bivalent and 
tetravalent binders. It was recently shown that 
certain combinations of mAbs are superior in 
controlling tumor growth by synergistically 
inhibiting receptor recycling after internalization 
(31, 32, 65, 66). In particular, mAbs engaging 
distinct epitopes accelerated net internalization 
by cross-linking EGFR on the cellular surface. 
As the previously selected group of DARPins 
targeted two distinct epitopes, two of these 
DARPins were combined: E01, having the 
highest affinity, and E69, targeting an epitope 
located on domain I, were chosen. Bispecific 
DARPins were constructed with a flexible 
linker, as well as with a leucine zipper. 
Bispecific DARPins connected through a 
flexible linker more effectively inhibited A431 
proliferation than the monovalent constructs, as 
seen in XTT assays, and induced G1 arrest 
(Fig. 4). Both orientations showed inhibition of 
phosphorylation of EGFR and ERK1/2 (Fig. 6). 
However, the Akt pathway was only affected to 
a lesser extent in comparison to the MAPK 
pathway. Since the A431 cell line depends both 
on the MAPK and Akt pathways for cell survival 
and proliferation (43), inhibition of long-term 
cell viability was limited, as confirmed by the 
clonogenic assay.  
 Interestingly, the E69_LZ3_E01 variant 
was particularly effective in inhibiting A431 
proliferation. In this molecule, each DARPin is 
also bivalent (Fig. 3B). The clonogenic assay 
showed a significant decrease in the survival 
fraction. Western blot analysis revealed that 
phosphorylation of EGFR and the signaling 
molecules ERK1/2 and Akt was inhibited, thus 
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affecting A431 cell viability and survival. The 
reverse orientation, E01_LZ3_E69, showed 
hardly any biological activity on A431 cells. 
Though E01_LZ3_E69 was able to bind to 
EGFR expressed on A431 cells, this orientation 
did not block epitopes on EGFR as efficiently as 
E69_LZ3_E01 (Suppl. Fig. S2). Thus, A431 cell 
proliferation and survival were not particularly 
affected by E01_LZ3_E69. A similar 
observation was made by Roovers et al., who 
combined two nanobodies both with epitopes 
located on domain III (67). They found that 
bispecific nanobody 9G8-7D12 induced EGFR 
phosphorylation and A431 cell proliferation; in 
contrast, the reverse orientation 7D12-9G8 did 
not cause receptor activation and therefore 
functioned as an antagonist.   
 In addition to the direct inhibition of 
signaling, total EGFR was significantly 
decreased after E69_LZ3_E01 treatment. To 
understand the mechanism of this effect, 
internalization and recycling assays according to 
(32) were performed. It was found that 
E69_LZ3_E01 efficiently prevented recycling of 
EGFR to the cellular surface, which was 
compared with the effect of the receptor 
recycling inhibitor monensin (Fig. 7). 
Monovalent E01 and E69 were unable to inhibit 
receptor recycling.  
 In this work, we have combined an EGFR 
domain I-binder with a domain III-binder where 
each of the binders is also bivalent. Spangler et 
al. showed that a combination of two domain III-
binders was the most effective in receptor down-
regulation, but found that a triepitopic format 
was the most optimal for biological activity (32, 
68). However, the extent of receptor down-
regulation induced by binding molecules likely 
depends on the receptor conformation and 
orientation. On A431 cells, EGFR is present in at 
least three different states, which differ in their 
degree of nanoscale and submicron scale 
clustering (69). In particular, the presence of 
higher order EGFR clusters in this cell line is 
distinctly different from the situation in which 
EGFR is expressed at a normal level; in the 
absence of high overexpression, EGFR is 
clustered in lower order clusters, i.e. monomers 
and dimers (69). Since E69_LZ3_E01 treatment 
down-regulates EGFR to a great extent, these 
DARPins, homodimerized via the leucine zipper, 
must be able to reach more than one EGFR 
molecule. In theory, the bispecific binders 
without leucine zipper might also be able to 
induce receptor clustering, but the short linker 
used in this study is most likely not suited since 
no change in surface EGFR was seen (Fig. 6). 
Thus, these molecules seem to contact only one 
EGFR molecule at a time. In summary, the 
leucine zipper seems to be the optimal construct; 
in this format, both DARPins are combined in 
one construct and are each bivalent, which 
makes expression convenient and 
straightforward. 
 In conclusion, we have established that 
three of the DARPins presented in this work 
exhibit a growth-inhibitory effect on A431 cells 
in vitro. By mapping their epitopes, we can infer 
that the biologically active DARPins E01 and 
E68 compete with the ligand binding site on 
EGFR without themselves causing a signal, thus 
blocking the receptor — a very useful feature of 
any EGFR targeting protein, even when carrying 
other effector functions. By linking DARPins 
E01 and E69, both targeting distinct epitopes, in 
a bispecific and bivalent format, the biological 
activity was significantly improved. The 
E69_LZ3_E01 construct could, in addition to its 
competitive inhibition of signaling, cross-link 
receptors on the cellular surface, leading to 
EGFR down-regulation. DARPin E69_LZ3_E01 
can therefore form the starting point for the 
addition of novel functions by linking other 
effector domains. In stark contrast to antibodies, 
such constructs can be prepared with very high 
yields in bacteria. Such DARPins may thus be 
able to form building blocks for future 
therapeutics. 
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FIGURE LEGENDS 
 
FIGURE 1. Epitope comparison and biological effects of monovalent DARPins binding to A431 
cells. Cetuximab is abbreviated as Cet. Each symbol or bar represents the average of three data points. 
(A) Epitope comparison using flow cytometry. DARPins on the x-axis were genetically fused to 
sfGFP. A431 cells were incubated with 100 nM sfGFP-tagged DARPin and 1 µM unlabeled DARPin, 
cetuximab or EGF (denoted by the differently shaded bars). E69 is the only DARPin that cannot be 
competed with any other DARPin, only with itself. (B) Inhibition of cell viability as determined by 
XTT assays. Cells were treated for 72 h with different concentrations of DARPins. DARPins E01, 
E67 and E68 affect the cell proliferation (Student’s t-test p<0.05 compared to untreated cells), 
whereas E69 and negative control Off7 do not. (C) Inhibition of cell proliferation as determined by 
clonogenic assays. A431 cells were treated for 7 days with 100 nM DARPin or 100 nM cetuximab, 
after which the medium was changed and cells were allowed to grow for another 7 days. E01, E67 
and E68 slightly inhibited cell proliferation, while E69 did not. (D) Cell cycle distribution. A431 cells 
were treated for 24 h with 100 nM DARPin or 100 nM cetuximab, after which cells were stained with 
propidium iodide and measured by flow cytometry. E01, E67 and E68 induced G1-arrest (Student’s t-
test p<0.05 compared to untreated cells), whereas E69 did not affect A431 cells.  
 
FIGURE 2. Epitopes of DARPins on EGFR and their spatial relation relative to bound EGF. (A) 
Comparison of the epitopes of E01, E68 and cetuximab on domain III of EGFR. EGFR residues 
involved in DARPin/cetuximab binding are in red, EGF in green stick representation. (B) Epitope of 
E69. EGFR residues involved in E69 binding are depicted in red, EGF is in green stick representation. 
(C) Overview of epitopes of E01 and E69. EGFR is shown in ribbon representation, with domain I in 
red, domain II in green, and domain III in blue, and part of domain IV in grey. The EGF ligand is 
shown in yellow in stick representation. Residues involved in E69 binding are shown in CPK 
representation in pink (domain I), and residues involved in either E01 or E68 binding are shown in 
CPK representation in cyan (domain III).  
 
FIGURE 3. Representations of the bispecific DARPins used in this work. (A) Model of the structure 
of E69_GS_E01. E69 (red) and E01 (blue) are both represented as cartoon, whereas the flexible linker 
(yellow) is represented in sticks. (B) Stick model of the structure of E69_LZ3_E01. E69 at the            
N-terminus is depicted in red, E01 in blue, the leucine zipper in green, and the linkers in yellow. 
 
FIGURE 4. Biological activity of bispecific DARPins with a flexible linker. Cetuximab is 
abbreviated as Cet. Each symbol or bar represents the average of three data points. (A) Inhibition of 
cell viability as determined by XTT assays. Cells were treated for 72 h with different concentrations 
of bivalent DARPins. A 1:1 mixture of DARPins E01 and E69, E01_GS_E69 and E69_GS_E01 
affect the cell proliferation similar to cetuximab (Student’s t-test p<0.05 compared to untreated cells); 
negative control DARPin Off7 does not. (B) Inhibition of cell proliferation as determined by 
clonogenic assays. A431 cells were treated for 7 days with 100 nM DARPin or 100 nM cetuximab, 
after which the medium was changed and cells were allowed to grow for another 7 days. (C) Cell 
cycle distribution. A431 cells were treated for 24 h with 100 nM DARPin or 100 nM cetuximab, after 
which cells were stained with propidium iodide and measured by flow cytometry. 
 
FIGURE 5. Biological activity of bispecific DARPins connected with a leucine zipper through 
different linkers. Cetuximab is abbreviated as Cet. Each symbol or bar represents the average of three 
data points. (A) Schematic overview of the constructs with different linker lengths. (B) Inhibition of 
A431 cell viability as determined by XTT assays. Cells were treated for 72 h with different 
concentrations of bispecific DARPins with flexible Gly-Ser linker or dimerizing leucine zipper, with 
E01 at the N-terminus and E69 at the C-terminus. E01_LZ1_E69 and E01_LZ2_E69 affect cell 
proliferation similar to cetuximab (Student’s t-test p<0.05 compared to untreated cells), whereas the 
negative control Off7 and E01_LZ3_E69 do not affect cell proliferation. (C) Inhibition of A431 cell 
viability as determined by XTT assays. Cells were treated for 72 h with different concentrations of 
bispecific DARPins with flexible Gly-Ser linker or dimerizing leucine zipper, with E69 at the N-
terminus and E01 at the C-terminus. E69_LZ1_E01 and E69_LZ3_E01 affect cell proliferation 
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similar to cetuximab (Student’s t-test p<0.05 compared to untreated cells), whereas negative control 
Off7 does not affect cell proliferation. DARPin E69_LZ2_E01 does affect cell proliferation, but to a 
lesser extent. (D) Inhibition of cell proliferation as determined by clonogenic assays. A431 cells were 
treated for 7 days with 100 nM DARPin or 100 nM cetuximab, after which the medium was changed 
and cells were allowed to grow for another 7 days. E69_LZ3_E01 significantly inhibited cell 
proliferation (Student’s t-test p<0.02 compared to untreated cells), whereas the other constructs had a 
less pronounced effect on cell proliferation. (E) Inhibition of cell proliferation as determined by 
clonogenic assays at different concentrations. A431 cells were treated with different concentrations of 
DARPin or cetuximab for 7 days, after which the medium was changed and cells were allowed to 
grow for another 7 days. Both cetuximab and E69_LZ3_E01 significantly inhibited cell proliferation 
(Student’s t-test p<0.02 and p<0.01, respectively), whereas negative control Off7 did not show an 
effect. The IC50 of E69_LZ3_E01 as determined from this graph is approximately 100 nM. (F, G) Cell 
cycle distribution. A431 cells were treated for 24 h with 100 nM bispecific DARPin with dimerizing 
leucine zipper or with 100 nM cetuximab, after which cells were stained with propidium iodide and 
measured by flow cytometry. The bispecific DARPins induced G1-arrest (Student’s t-test p<0.05 
compared to untreated cells), while E69_LZ3_E01 in particular significantly induced G1-arrest 
(Student’s t-test p<0.02 compared to untreated cells). 
 
FIGURE 6. Effect of DARPin treatment on downstream signaling. A431 cells were treated for 24 h 
with 100 nM cetuximab or 100 nM DARPin. Cells were then stimulated with 10 ng/ml EGF, except 
cells from sample “None -EGF”. Cell lysate corresponding to 20 µg protein was loaded onto an SDS-
PAGE gel; proteins were then transferred by Western blot and detected by a fluorescently labeled 
secondary antibody. A digital image of the fluorescently stained Western blot is shown above and a 
quantitation of the band intensity below. (A) Detection of EGFR and pEGFR (Y1068). E69_LZ3_E01 
dramatically reduces total EGFR. (B) Detection of ERK1/2 and pERK1/2 (T202/Y204). 
E01_GS_E69, E69_GS_E01 and E69_LZ3_E01 inhibit ERK1/2 phosphorylation dramatically. 
(C) Detection of Akt and pAkt (S473). E69_LZ3_E01 inhibits Akt phosphorylation to some extent.  
 
FIGURE 7. EGFR down regulation by E69_LZ3_E01 is caused by an inhibition of receptor 
recycling. (A) A431 cells were treated for 2 h with 100 nM DARPin_Alexa Fluor 488 at 37°C to 
allow for internalization of the EGFR:DARPin complex. Residual fluorescence outside the cell was 
quenched by an anti-Alexa quenching antibody, while fluorescence from recycled EGFR:DARPin 
complexes was chased by unlabeled DARPin. The fluorescence signal from internalized receptor-
DARPin complex was measured and compared to an untreated control. E69_LZ3_E01 was able to 
inhibit recycling back to the surface, whereas E01 alone as well as in combination with E69 did not. 
(B) A431 cells were treated for 20 min with the receptor recycling inhibitor monensin or with 
E69_LZ3_E01. At the indicated time points, residual surface EGFR was analyzed by flow cytometry. 
E69_LZ3_E01 was able to inhibit receptor recycling to the same extent as monensin. (C) Schematic 
overview of the biological effect of DARPin E69_LZ3_E01 on A431 cells overexpressing EGFR. 
DARPin E69 is depicted in red, whereas E01 is depicted in blue; the DARPins are connected via a 
leucine zipper. Upon treatment of A431 cells with the DARPin, EGFR on the cellular surface will 
organize in clusters. These clusters are internalized via clathrin-coated pits into the early endosome. 
Normally, EGFR will be recycled back to the cellular surface via the recycling endosome; in the case 
of E69_LZ3_E01, however, recycling is inhibited and total surface EGFR is diminished. This has a 
strong impact on cell proliferation and downstream signaling events. 
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